{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-130763","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.177374+00:00","generated_at":"2026-05-29T17:54:52.173389+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Aptevo's Peter Pavlik to present ADAPTIR platform at Pep Talk; new molecule expected in early 2025","bullets":["Peter Pavlik, PhD, will chair a 'Bi and Multispecific Biologics' session at Pep Talk conference in January 2025.","Presentation will highlight ADAPTIR platform using clinical candidates Mipletamig and ALG.APV-527 as proof of concept.","Aptevo has five compounds in clinical/preclinical development and plans a new molecule in early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-130763","json":"https://secwatch.observer/filing/0000950170-24-130763.json","markdown":"https://secwatch.observer/filing/0000950170-24-130763.md","text":"https://secwatch.observer/filing/0000950170-24-130763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024130763/0000950170-24-130763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024130763/apvo-20241126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T17:54:52.173389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}